Developing new treatments for Duchenne Muscular Dystrophy using oligonucleotides
Development of Utrophin Site Blocking Oligos (SBOs) to Treat Duchenne Muscular Dystrophy (DMD)
This study is looking for a new way to help boys with Duchenne Muscular Dystrophy by using special treatments that could boost a protein called utrophin to improve their muscle strength and health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10678195 on NIH RePORTER |
What this research studies
This research focuses on finding a new treatment for Duchenne Muscular Dystrophy (DMD), a severe genetic disorder that primarily affects boys. The approach involves using specially designed oligonucleotides to block certain microRNAs that inhibit the production of utrophin, a protein that can compensate for the missing dystrophin in DMD patients. By increasing utrophin levels, the research aims to improve muscle function and overall health in individuals with DMD. The study will involve testing these oligonucleotides in animal models to assess their effectiveness and safety before considering human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are boys diagnosed with Duchenne Muscular Dystrophy, particularly those who are in the early stages of the disease.
Not a fit: Patients with other forms of muscular dystrophy or those who are in advanced stages of Duchenne Muscular Dystrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that improves muscle function and quality of life for patients with Duchenne Muscular Dystrophy.
How similar studies have performed: Previous research has shown promise in using similar oligonucleotide approaches to increase utrophin levels, indicating a potential for success in this novel treatment strategy.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Khurana, Tejvir S — University of Pennsylvania
- Study coordinator: Khurana, Tejvir S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.